Novartis AG is 204.3x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($293.70 B vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KALV | NVS |
|---|---|---|
| Market cap | $1.44 B | $293.70 B |
| US-listed rank | #2377 | #46 |
| Revenue (latest FY) | $50.00M | - |
| Net income (latest FY) | -$183.40M | - |
| Net margin | -366.8% | - |
| SEC filings | 834 | 947 |
Novartis AG is 204.3x more valuable than KalVista Pharmaceuticals, Inc. by market capitalization ($293.70 B vs $1.44 B).
Full pages: KalVista Pharmaceuticals, Inc. and Novartis AG, or browse the full rankings.